PRMT5 and breast carcinoma: This is exemplified by the activation of FOXP1 transcription in breast cancer stem cells [38] and DVL3 transcription, an activator of Wnt/β-catenin, in CML-LSCs (leukemic stem cells) [131], which were linked with PRMT5 activity.